Clincosm LogoSign in Get a demo

Application of Biomarkers in Neurological Diseases

Sponsor
Yi Yang (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05881226
Collaborator
(none)
3,000
Enrollment
1
Location
102
Anticipated Duration (Months)
29.4
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

To explore the predictive and diagnostic role of biomarkers in patients with neurological diseases.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    With the rise and continuous development of omics technology and bioinformatics technology, some scholars have applied proteomics technology and metabolomics technology to study the brain tissue, plasma and CSF of patients with nervous system diseases, so as to screen out potential biomarkers, with a view to providing new research ideas for pathogenesis and early diagnosis of neurological diseases. At present, the research on some novel biomarkers is still in its infancy, and many key problems remain to be solved. It is necessary to further determine the expression level of biomarkers in normal human body and the characteristics of biomarkers in patients with neurological diseases.

    Study Design

    Study Type:
    Observational [Patient Registry]
    Anticipated Enrollment :
    3000 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Application of Biomarkers in Neurological Diseases
    Anticipated Study Start Date :
    Jun 1, 2023
    Anticipated Primary Completion Date :
    Dec 1, 2030
    Anticipated Study Completion Date :
    Dec 1, 2031

    Arms and Interventions

    Arm Intervention/Treatment
    Patients admitted to hospital/emergency department with neurological diseases

    All clinical data, laboratory data and imaging data of patients at baseline and follow-up were collected, as well as blood and tissue samples that did not affect the diagnosis and treatment of patients after obtaining the consent of patients at different time points in the acute and chronic phases.

    Outcome Measures

    Primary Outcome Measures

    1. mRS score in 90 days [3 months]

      The proportion of 3-month good functional outcome (mRS Score 0-2) in patients with neurological diseases was evaluated by mRS Score

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    1. Patients with neurological diseases;

    2. Subjects or legal agents agree to participate in the study and sign the informed consent.

    Exclusion Criteria:

    1. Participating in other clinical investigators;

    2. Unwilling to be followed up or poor treatment compliance;

    3. Other conditions considered unsuitable for inclusion by the researchers.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 First Hospital of Jilin University Changchun Jilin China 130000

    Sponsors and Collaborators

    • Yi Yang

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Yi Yang, Associated Dean of First Hospital of Jilin University, The First Hospital of Jilin University
    ClinicalTrials.gov Identifier:
    NCT05881226
    Other Study ID Numbers:
    • Bio-Neuro
    First Posted:
    May 31, 2023
    Last Update Posted:
    May 31, 2023
    Last Verified:
    May 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Nervous System Diseases

    Study Results

    No Results Posted as of May 31, 2023